{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:14:23Z","timestamp":1793297663255,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020141","name":"Akebia Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jacl.2022.08.008","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T02:01:59Z","timestamp":1663812119000},"page":"833-849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study"],"prefix":"10.1016","volume":"16","author":[{"given":"Elif A.","family":"Oral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhimanyu","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1076-9687","authenticated-orcid":false,"given":"Eric A.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis St.L.","family":"O'Dea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoly","family":"Tiulpakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica J.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnetta","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunju","family":"Hurh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5195-6614","authenticated-orcid":false,"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6308-3179","authenticated-orcid":false,"given":"Richard S.","family":"Geary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2022.08.008_bib0001","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.08.008_bib0002","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2147\/DMSO.S206053","article-title":"Familial partial lipodystrophy (FPLD): recent insights","volume":"13","author":"Bagias","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jacl.2022.08.008_bib0003","unstructured":"Familial Partial Lipodystrophy. National Organization for Rare Disorders; 2015. Available at https:\/\/rarediseases.org\/rare-diseases\/familial-partial-lipodystrophy\/#:\u223c:text=Familial Accessed June 22, 2022."},{"key":"10.1016\/j.jacl.2022.08.008_bib0004","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/db19-0447","article-title":"Clinical and molecular prevalence of lipodystrophy in an unascertained large clinical care cohort","volume":"69","author":"Gonzaga-Jauregui","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.jacl.2022.08.008_bib0005","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86870","article-title":"Whole-exome sequencing identifies ADRA2A mutation in atypical familial partial lipodystrophy","volume":"1","author":"Garg","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacl.2022.08.008_bib0006","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.bbalip.2019.02.002","article-title":"Gene-gene and gene-environment interactions in lipodystrophy: lessons learned from natural PPAR\u03b3 mutants","volume":"1864","author":"Broekema","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.jacl.2022.08.008_bib0007","first-page":"3431","article-title":"Heterogeneity of nuclear lamin A mutations in Dunnigan-type familial partial lipodystrophy","volume":"85","author":"Hegele","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2022.08.008_bib0008","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","article-title":"The clinical approach to the detection of lipodystrophy\u2014an AACE consensus statement","volume":"19","author":"Handelsman","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacl.2022.08.008_bib0009","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2147\/DMSO.S188856","article-title":"Hypertriglyceridemia-related pancreatitis In patients with type 2 diabetes: links and risks","volume":"12","author":"Shemesh","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jacl.2022.08.008_bib0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0002-9343(99)00414-3","article-title":"Lipodystrophies","volume":"108","author":"Garg","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2022.08.008_bib0011","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-Acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2022.08.008_bib0012","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jacl.2022.08.008_bib0013","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jc.2006-2676","article-title":"Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism","volume":"93","author":"Chan","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2022.08.008_bib0014","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MED.0000000000000136","article-title":"Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease","volume":"22","author":"Kohan","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jacl.2022.08.008_bib0015","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.08.008_bib0016","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2022.08.008_bib0017","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MOL.0b013e328352dc70","article-title":"Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production","volume":"23","author":"Yao","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2022.08.008_bib0018","unstructured":"The BROADEN Study: A Study of Volanesorsen (Formerly ISIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy. ClinicalTrials.gov; 2020. NCT02527343 Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02527343. Accessed June 22, 2022."},{"key":"10.1016\/j.jacl.2022.08.008_bib0019","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1148\/radiol.14140754","article-title":"Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease","volume":"274","author":"Tang","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.jacl.2022.08.008_bib0020","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2022.08.008_bib0021","series-title":"Characterising Familial Partial Lipodystrophy: Baseline Data of the BROADEN Study [poster]","author":"O'Dea","year":"2020"},{"key":"10.1016\/j.jacl.2022.08.008_bib0022","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.08.008_bib0023","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","article-title":"Apolipoprotein C-III: from pathophysiology to pharmacology","volume":"36","author":"Norata","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jacl.2022.08.008_bib0024","doi-asserted-by":"crossref","first-page":"bvaa191","DOI":"10.1210\/jendso\/bvaa191","article-title":"Apolipoprotein CIII and angiopoietin-like protein 8 are elevated in lipodystrophy and decrease after metreleptin","volume":"5","author":"Lightbourne","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.jacl.2022.08.008_bib0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2022.08.008_bib0026","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jacl.2018.05.013","article-title":"Characterizing familial chylomicronemia syndrome: baseline data of the APPROACH study","volume":"12","author":"Blom","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2022.08.008_bib0027","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacl.2021.07.004","article-title":"Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2","volume":"15","author":"Lazarte","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2022.08.008_bib0028","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/nu13041075","article-title":"Come back skinfolds, all is forgiven: a narrative review of the efficacy of common body composition methods in applied sports practice","volume":"13","author":"Kasper","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.jacl.2022.08.008_bib0029","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422002501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422002501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:38:07Z","timestamp":1761831487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287422002501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1933287422002501"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2022.08.008","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2022.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2022.06.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}